The influence of sex on pharmacokinetics, Clin Pharmacokinet, 2003. ,
Biologic and molecular mechanisms for sex differences in pharmacokinetics, pharmacodynamics, and pharmacogenetics: Part I, J Womens Health Gend Based Med, vol.11, pp.601-616, 2002. ,
Global, regional, and subregional trends in unintended pregnancy and its outcomes from 1990 to 2014: estimates from a Bayesian hierarchical model, Lancet Glob Health, vol.6, pp.380-389, 2018. ,
, Committee Opinion No. 646: Ethical Considerations for Including Women as Research Participants, Obstet Gynecol, vol.127, pp.1127-1135, 2016.
, Clinical Trial Facilitation Group. Recommendations related to contraception and
Descriptive study on contraceptive requirements for clinical trials in Spain ,
, Med Clin (Barc), vol.132, pp.70-74, 2009.
Exclusion of Women of Childbearing Potential in Clinical Trials of Type 2 Diabetes Medications: A Review of Protocol-Based Barriers to Enrollment, Diabetes Care, vol.39, pp.1004-1013, 2016. ,
A Systematic Review of Inclusion of Women of Childbearing Potential (WOCP) in NIH Clinical Trials: Contraception and Pregnancy Testing, AER Conference: Navigating the Future Using the Belmont Compass, 2009. ,
,
Birth Control in Clinical Trials: Industry Survey of Current Use Practices, Governance, and Monitoring, Ther Innov Regul Sci, vol.50, pp.155-68, 2016. ,
Contraceptive choices, pregnancy rates, and outcomes in a microbicide trial, Obstet Gynecol, vol.118, pp.895-904, 2011. ,
Contraceptive Use and Pregnancy Incidence Among Women Participating in an HIV Prevention Trial, J Womens Health, 2017. ,